The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising demand for personalized medicine and high-throughput solutions. Innovations in automated and precise fractionation technologies are expanding applications in genomics, proteomics, and biopharmaceuticals, especially for cancer and neurodegenerative disease research. The market sees strong growth in consumables and instruments, with significant opportunities in the U.S., China, Japan, and Europe.
Merck & Co., Inc. (MRK) holds a market cap of $362.83 billion and trades at USD 147.25 as of Nov 12, 2026, 22:13 WIB on Pluang, with a slight 1-day gain of 0.04%. Despite the strong sell order activity at 99%, Merck remains a key player in the growing cell lysis and fractionation market highlighted in the report. The enterprise value stands at $406.96 billion, reflecting its significant presence in the health sector amid the expanding biotechnology landscape.
